2017
DOI: 10.1111/ped.13433
|View full text |Cite
|
Sign up to set email alerts
|

Congenital cytomegalovirus in Japan: More than 2 year follow up of infected newborns

Abstract: Background: The aim of this study was to evaluate the outcome of congenital cytomegalovirus (CMV) infection identified on urine-filter screening assay at >2 years' follow up, and to observe the clinical outcomes after anti-CMV treatment. Methods: Sixty of 72 congenital CMV patients were enrolled and clinically observed for >2 years. Forty-three were asymptomatic at birth; seven were symptomatic at birth but untreated with anti-CMV drugs; and 10 were symptomatic and treated with anti-CMV drugs. Results: Of the … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
49
2

Year Published

2020
2020
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 22 publications
(52 citation statements)
references
References 22 publications
1
49
2
Order By: Relevance
“…None of the cCMV-infected infants who completed assessments had SNHL. Late onset SNHL may manifest after 12 months of age as described by others [2,24,25]. A Brazilian study, also from a high CMV sero-immune population, reported SNHL prevalence of 8.6%…”
Section: Plos Onementioning
confidence: 71%
See 1 more Smart Citation
“…None of the cCMV-infected infants who completed assessments had SNHL. Late onset SNHL may manifest after 12 months of age as described by others [2,24,25]. A Brazilian study, also from a high CMV sero-immune population, reported SNHL prevalence of 8.6%…”
Section: Plos Onementioning
confidence: 71%
“…(5/58, 95% CI 2.9-19.0) in cCMV infected children at a median age of 24 months (range 15-50 months) [2]. In a Japanese study, one (2.3%) of 43 asymptomatic cCMV cases at birth developed SNHL by 12 months of age compared to 12 (70.6%) of 17 symptomatic children [24]. Three children in our study also received oral valganciclovir therapy, which has been shown to improve hearing outcomes [26].…”
Section: Plos Onementioning
confidence: 98%
“…[ 1 , 2 ] Birth prevalence of CMV-positive infants in developed countries was estimated to be 0.2% to 0.7%: of these, 10% to 30% are considered to be symptomatic at birth, and most of these develop long-term sequelae. [ 1 , 3 9 ] Recent studies from Japan also reported similar estimates for the birth prevalence of cCMV (0.26%–0.31%) [ 7 , 8 , 10 ] and the proportion of symptomatic patients (24%–30%). [ 7 , 10 ] These estimates, however, generally come from hospital-based prospective studies where the enrolled infants underwent extensive examinations and monitoring.…”
Section: Introductionmentioning
confidence: 70%
“…[ 7 , 10 ] These estimates, however, generally come from hospital-based prospective studies where the enrolled infants underwent extensive examinations and monitoring. [ 3 10 ] Much lower prevalence was observed in the studies based on surveillance, [ 11 13 ] questionnaire surveys, [ 14 , 15 ] or medical claims, [ 16 , 17 ] raising concerns about limited awareness and underdiagnosis of the disease in real-world clinical practices. [ 13 , 16 ]…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation